Lilly plans Phase III for eloralintide combo after weight-loss win

1 October 2026

US pharma major Eli Lilly (NYSE: LLY) plans to begin Phase III trials of its experimental obesity combination EloraTZP by year-end, after a mid-stage study found that its highest dose produced average weight loss of 23.3% in adults with overweight or obesity and type 2 diabetes.

The treatment pairs the investigational amylin receptor agonist eloralintide with tirzepatide, the active ingredient in Zepbound. Lilly reported greater weight loss with the highest-dose combination than with either component alone, although gastrointestinal side effects were more frequent in the combination groups.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK